Conformation and Membrane Topology of the N-Terminal Ectodomain of Influenza A M2 Protein

被引:0
作者
Roeke, Kyra C. [1 ]
Howard, Kathleen P. [1 ]
机构
[1] Swarthmore Coll, Dept Chem & Biochem, Swarthmore, PA 19081 USA
基金
美国国家卫生研究院;
关键词
influenza; M2; protein; ectodomain; spin labels; EPR; universal vaccine; PROTON CHANNEL; LIPID-BILAYERS; EXTRACELLULAR DOMAIN; MATRIX PROTEIN-2; ION-CHANNEL; VIRUS; DRUG; CHOLESTEROL; MECHANISM; BINDING;
D O I
10.3390/membranes15020040
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The N-terminal ectodomain of the influenza A M2 protein is a target for universal influenza vaccine development and novel antiviral strategies. Despite the significance of this domain, it is poorly understood and most structural studies of the M2 protein have disregarded the N-terminal ectodomain in their analyses. Here, we report conformational properties and describe insights into the membrane topology of sites along the N-terminal ectodomain. Full-length M2 protein is embedded in lipid bilayer nanodiscs and studied using site-directed spin labeling electron paramagnetic resonance spectroscopy. Results are consistent with a turn in the middle of the ectodomain that changes in proximity to the membrane surface upon the addition of cholesterol or the antiviral drug rimantadine. Similarly to other domains of M2 protein, lineshape analysis suggests that the N-terminal ectodomain can adopt multiple conformations.
引用
收藏
页数:12
相关论文
共 42 条
  • [1] Paules C., Subbarao K., Influenza, Lancet, 390, pp. 697-708, (2017)
  • [2] Han A.X., De Jong S.P.J., Russell C.A., Co-evolution of immunity and seasonal influenza viruses, Nat. Rev. Microbiol, 21, pp. 805-817, (2023)
  • [3] Kandeil A., Patton C., Jones J.C., Jeevan T., Harrington W.N., Trifkovic S., Seiler J.P., Fabrizio T., Woodard K., Turner J.C., Et al., Rapid evolution of A(H5N1) influenza viruses after intercontinental spread to North America, Nat. Commun, 14, (2023)
  • [4] Hayden F.G., Asher J., Cowling B.J., Hurt A.C., Ikematsu H., Kuhlbusch K., Lemenuel-Diot A., Du Z., Meyers L.A., A Piedra P., Et al., Reducing Influenza Virus Transmission: The Potential Value of Antiviral Treatment, Clin. Infect. Dis, 74, pp. 532-540, (2022)
  • [5] Yin H., Jiang N., Shi W., Chi X., Liu S., Chen J.-L., Wang S., Development and Effects of Influenza Antiviral Drugs, Molecules, 26, (2021)
  • [6] Gu R.-X., Liu L.A., Wei D.-Q., Structural and energetic analysis of drug inhibition of the influenza A M2 proton channel, Trends Pharmacol. Sci, 34, pp. 571-580, (2013)
  • [7] Park E.K., Castrucci M.R., Portner A., Kawaoka Y., The M2 Ectodomain Is Important for Its Incorporation into Influenza A Virions, J. Virol, 72, pp. 2449-2455, (1998)
  • [8] Schepens B., De Vlieger D., Saelens X., Vaccine options for influenza: Thinking small, Curr. Opin. Immunol, 53, pp. 22-29, (2018)
  • [9] Matthys A., Saelens X., Promises and challenges of single-domain antibodies to control influenza, Antivir. Res, 222, (2024)
  • [10] Yu C., Ding W., Zhu L., Zhou Y., Dong Y., Li L., Liu J., Wang Y., Li Z., Zhu L., Et al., Screening and characterization of inhibitory vNAR targeting nanodisc-assembled influenza M2 proteins, iScience, 26, (2023)